Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
Carsten Utoft Niemann, Mark‐David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, G.J. Veldhuis, Rogier Mous, Clemens Mellink, Johan A. Dobber, Christian Bjørn Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa Tran, Kazem Nasserinejad, Arnon P. Kater
Abstract
Funding Information: The work was supported by AbbVie and Janssen who also provided study drugs and had the option to comment on the manuscript. Funding Information: The authors thank all participating patients, local data managers for study coordination and patient data collection, local investigators, and, in particular, the study team at the HOVON Data Center at the Erasmus MC Cancer Institute and the 2 central laboratories at Amsterdam UMC and Rigshospitalet. The work was supported by AbbVie and Janssen who also provided study drugs and had the option to comment on the manuscript. The investigators are independent data owners with unrestricted publication rights.